🇺🇸 FDA

Intelligence · Clinical Pipeline

Phase II Pipeline Programs

Proof-of-concept and dose-finding clinical programs in Phase II development.

Programs
7,238

Quick answer

NovaPharmaNews tracks 7,238 phase ii pharmaceutical pipeline programs from ClinicalTrials.gov. Proof-of-concept and dose-finding clinical programs in Phase II development.

Top sponsors

Page 11 of 151

  1. ASTX727

    Taiho Pharma Netherlands B.V.

    Acute myeloid lymphoma (AML), myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML) or solid tumors

    phase 2 small molecule active

    1 trial

  2. ASTX727, Venclyxto 50 mg film-coated tablets, Venclyxto 10 mg film-coated tablets, Venclyxto 100 mg film-coated tablets

    Taiho Pharma Netherlands B.V.

    Acute Myeloid Leukemia (AML)

    phase 2 small molecule active

    1 trial

  3. ASTX727, YERVOY 5 mg/ml concentrate for solution for infusion, OPDIVO 10 mg/mL concentrate for solution for infusion.

    Fondazione Telethon ETS

    MM and NSCLC patients resistant to anti-PD-1/PD-L1 therapy

    phase 2 small molecule active

    1 trial

  4. AT-1501

    Eledon Pharmaceuticals

    Kidney Transplant Rejection

    phase 2 small molecule active

    2 trials

  5. AT-1501

    Eledon Pharmaceuticals

    Type 1 Diabetes Mellitus

    phase 2 small molecule terminated

    1 trial

  6. AT-1501

    Eledon Pharmaceuticals

    IgA Nephropathy

    phase 2 small molecule terminated

    1 trial

  7. AT-1501

    Eledon Pharmaceuticals

    Amyotrophic Lateral Sclerosis

    phase 2 small molecule completed

    1 trial

  8. AT-1501

    Eledon Pharmaceuticals

    Prevention of Rejection in Kidney Transplant

    phase 2 small molecule active

    1 trial

  9. AT-1501 IV Infusion

    Eledon Pharmaceuticals

    Brittle Type 1 Diabetes Mellitus

    phase 2 mab terminated

    1 trial

  10. AT-527

    Atea Pharmaceuticals

    COVID-19

    phase 2 small molecule terminated

    2 trials

  11. AT-527

    Atea Pharmaceuticals

    Hepatitis C

    phase 2 small molecule completed

    1 trial

  12. AT-752

    Atea Pharmaceuticals

    Dengue Fever

    phase 2 small molecule terminated

    1 trial

  13. AT-777

    Atea Pharmaceuticals

    Hepatitis C

    phase 2 small molecule terminated

    1 trial

  14. ATA188

    Evidence Based Cataract Study Group

    Primary Progressive Multiple Sclerosis

    phase 2 mab terminated

    1 trial

  15. ATEZOLIZUMAB

    The George Institute

    Patients with metastatic tumours (colorectal, non-small cell lung, renal and sarcoma)

    phase 2 small molecule active

    1 trial

  16. ATEZOLIZUMAB, COBIMETINIB, VEMURAFENIB

    Fondazione Telethon ETS

    high-risk, surgically resectable BRAF mutated and wild-type Melanoma

    phase 2 small molecule active

    1 trial

  17. ATH434

    ALTERITY THERAPEUTICS LTD

    Multiple System Atrophy

    phase 2 small molecule completed

    1 trial

  18. ATH434 dose level 1

    ALTERITY THERAPEUTICS LTD

    Multiple System Atrophy

    phase 2 small molecule completed

    1 trial

  19. ATH434-DP2

    ALTERITY THERAPEUTICS LTD

    Multiple System Atrophy

    phase 2 small molecule active

    1 trial

  20. ATI 502 0.46% Topical Solution

    Aclaris Therapeutics

    Alopecia Areata

    phase 2 small molecule terminated

    1 trial

  21. ATI-045

    Aclaris Therapeutics

    Atopic Dermatitis

    phase 2 small molecule active

    1 trial

  22. ATI-045, Placebo to ATI-045

    Aclaris Therapeutics

    Atopic dermatitis

    phase 2 small molecule active

    1 trial

  23. ATI-1777

    Aclaris Therapeutics

    Atopic Dermatitis

    phase 2 small molecule completed

    1 trial

  24. ATI-1777 2.0% w/w

    Aclaris Therapeutics

    Atopic Dermatitis

    phase 2 small molecule completed

    1 trial

  25. ATI-2138

    Aclaris Therapeutics

    Atopic Dermatitis

    phase 2 small molecule completed

    1 trial

  26. ATI-450

    Aclaris Therapeutics

    Cryopyrin-Associated Periodic Syndrome

    phase 2 small molecule terminated

    1 trial

  27. ATI-450

    Aclaris Therapeutics

    Rheumatoid Arthritis

    phase 2 small molecule completed

    1 trial

  28. ATI-450

    Aclaris Therapeutics

    Hidradenitis Suppurativa

    phase 2 small molecule completed

    1 trial

  29. ATI-450

    Aclaris Therapeutics

    Psoriatic Arthritis

    phase 2 small molecule terminated

    1 trial

  30. ATI-450 50 mg oral tablet BID

    Aclaris Therapeutics

    Rheumatoid Arthritis

    phase 2 small molecule completed

    1 trial

  31. ATI-50002

    Aclaris Therapeutics

    Androgenetic Alopecia

    phase 2 small molecule completed

    1 trial

  32. ATI-50002

    Aclaris Therapeutics

    Alopecia Areata

    phase 2 small molecule completed

    1 trial

  33. ATI-50002 high dose

    Aclaris Therapeutics

    Alopecia Areata

    phase 2 small molecule terminated

    1 trial

  34. ATI-50002 topical solution

    Aclaris Therapeutics

    Vitiligo

    phase 2 small molecule completed

    1 trial

  35. ATI-501 400mg BID (Low dose)

    Aclaris Therapeutics

    Alopecia

    phase 2 small molecule completed

    1 trial

  36. ATI-502

    Aclaris Therapeutics

    Atopic Dermatitis

    phase 2 small molecule completed

    1 trial

  37. ATM

    BRIGHT MINDS BIOSCIENCES INC.

    Dual Diagnosis

    phase 2 other completed

    1 trial

  38. ATRN-119

    Aprea Therapeutics

    Advanced Solid Tumor

    phase 2 small molecule active

    1 trial

  39. ATRN-119

    Aprea Therapeutics

    HPV Positive Oropharyngeal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  40. AU-011

    Aura Biosciences

    Eye Cancer

    phase 2 small molecule active

    1 trial

  41. AU-011

    Aura Biosciences

    Uveal Melanoma

    phase 2 small molecule completed

    1 trial

  42. AUR103 Calcium

    Disc Medicine

    HER 2 Positive Gastric Cancer

    phase 2 small molecule terminated

    1 trial

  43. AUR200, Isotone Natriumchloridlösung 0,9 % Braun Injektionslösung

    Aurinia Pharmaceuticals

    Generalized Myasthenia Gravis

    phase 2 small molecule active

    1 trial

  44. AUTO CAR T cell therapy

    Autolus GmbH

    Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy

    phase 2 mab active

    1 trial

  45. AUTO1

    Autolus GmbH

    Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia

    phase 2 mab active

    2 trials

  46. AUTO1, Cyclophosphamide 500 mg Powder for Solution for Injection or Infusion, Fludara 50 mg powder for solution for injection or infusion

    Autolus GmbH

    Systemic Lupus Erythematosus with Active Lupus Nephritis

    phase 2 small molecule active

    1 trial

  47. AUTO1, MabThera 500 mg concentrate for solution for infusion, AUTO4, MabThera 100 mg concentrate for solution for infusion

    Autolus GmbH

    Potential malignancy in patients who received treatment with Autolus CAR T cell therapy.

    phase 2 small molecule active

    1 trial

  48. AUTO2

    Autolus GmbH

    Multiple Myeloma

    phase 2 mab terminated

    1 trial

Frequently asked questions

How many Phase II pipeline programs are in the directory?

7,238 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.